Compare abrdn Physical Palladium Shares ETF (PALL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Physical Palladium Shares ETF vs Recursion Pharmaceuticals Inc — how do they compare? abrdn Physical Palladium Shares ETF trades at $20.95 (market cap $586.03M), while Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.7× abrdn Physical Palladium Shares ETF's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold abrdn Physical Palladium Shares ETF for 33 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PALL | RXRX | |
|---|---|---|
Market Cap | $586.03M | $2.14B |
Volume | 1,257,028 | 30,789,535 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.18 | $6.79 |
52-Week Low | $20.30 | $2.84 |
Typical Hold Time | 33 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PALL (Aberdeen Physical Palladium Shares ETF) trades at $20.30, down 4.47% with bearish technical signals from moving averages but bullish RSI readings. The ETF tracks palladium prices, which have declined 47% from January 2026 highs. Recent news highlights palladium's underperformance versus gold and silver, with some analysts viewing current levels as a buying opportunity given supply risks and industrial demand.
PALL presents a contrarian opportunity as palladium approaches technical support levels, though the metal faces headwinds from automotive sector volatility. The ETF's value depends entirely on palladium price movements rather than company fundamentals, creating pure commodity exposure with significant price volatility risk.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
